Sonova (OTCMKTS:SONVY) versus Rapid Micro Biosystems (NASDAQ:RPID) Critical Comparison

Sonova (OTCMKTS:SONVY) and Rapid Micro Biosystems (NASDAQ:RPID) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Volatility & Risk

Sonova has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Rapid Micro Biosystems has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Earnings & Valuation

This table compares Sonova and Rapid Micro Biosystems”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sonova	$4.36 billion	3.04	$610.01 million	N/A	N/A
Rapid Micro Biosystems	$33.59 million	2.94	-$47.12 million	($1.07)	-2.03

Sonova has higher revenue and earnings than Rapid Micro Biosystems.

Profitability

This table compares Sonova and Rapid Micro Biosystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sonova	N/A	N/A	N/A
Rapid Micro Biosystems	-140.30%	-95.40%	-58.85%

Insider and Institutional Ownership

0.0% of Sonova shares are held by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are held by institutional investors. 0.0% of Sonova shares are held by insiders. Comparatively, 30.0% of Rapid Micro Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Sonova and Rapid Micro Biosystems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sonova	1	4	1	2	2.50
Rapid Micro Biosystems	1	0	1	0	2.00

Rapid Micro Biosystems has a consensus price target of $8.00, indicating a potential upside of 268.66%. Given Rapid Micro Biosystems’ higher probable upside, analysts clearly believe Rapid Micro Biosystems is more favorable than Sonova.

Summary

Sonova beats Rapid Micro Biosystems on 8 of the 12 factors compared between the two stocks.

About Sonova

Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.